Match Document Document Title
10111913 Method of reducing the likelihood of skin cancer in an individual human being  
Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria and other...
10111901 Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment  
The present invention relates to the combination of soluble β-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment,...
10111899 Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung  
The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable...
10111897 Compositions and methods for treating cancer with JAK2 activity  
Methods and compositions for diagnosing and treating JAK2 inhibitor resistant cancers are disclosed. In the disclosed methods, AKT and/or PI3K inhibitors, ERK/MEK inhibitors, BCL-XL protein...
10111896 Composition comprising a combination of DNA methylation inhibitor and a vitamin D receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapse  
The present invention concerns a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for simultaneous or sequential use in the treatment of a drug resistant...
10111892 Anti-cancer agent  
The anti-cancer agent of the present invention contains at least one kind of phosphine transition metal complex selected from a group of compounds represented by the following Formulae (1a) to...
10111878 N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer  
Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of...
10111874 Combination therapies for treatment of cancer  
Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with...
10111871 Nanoparticle drug delivery system and method of treating cancer and neurotrauma  
The invention provides pharmaceutical formulations of inhibitors for poly (ADP-ribose) polymerase (PARP) enzyme. The formulations can be used in the treatment and prevention of cancer as well as...
10111861 Treatment of breast cancer  
This disclosure describes the use of one or more compounds that fall within the scope of one or more structural formula I, II, III, IV, V, or VI for treating triple negative breast cancer....
10111852 Method for treating bladder cancer  
A method for treating bladder cancer including the steps of administering an isothiocyanate functional surfactant to an area affected by bladder cancer, wherein the isothiocyanate functional...
10111632 System and method for breast cancer detection in X-ray images  
For breast cancer detection with an x-ray scanner, a cascade of multiple classifiers is trained or used. One or more of the classifiers uses a deep-learnt network trained on non-x-ray data, at...
10111604 Portable apparatus for detecting breast cancer  
An apparatus for detecting abnormal masses such as breast cancer includes a measurement sensor configured to obtain a voltage at a first area of a first breast of a subject; a reference sensor...
10107817 Oligopeptide specific to ovarian cancer, polynucleotide for encoding oligopeptide, test kit for detecting ovarian cancer and method for detecting ovarian cancer  
The present disclosure relates to an oligopeptide which is highly specific to an ovarian cancer. The oligopeptide includes an amino acid sequence of SEQ ID NO: 1. The present disclosure also...
10107778 System and method for detecting lysyl oxidase-like 2 protein (LOXL2) and breast cancer  
A detection system for determining lysyl oxidase-like 2 protein (LOXL2) levels in a bodily sample, includes at least one reaction solution for generating H2O2 upon combination with LOXL2 in the...
10106854 Biomarkers for prostate cancer  
The present application concerns methods and tools for diagnosing prostate cancer and furthermore concerns methods and tools for prognosing disease progression of prostate cancer. The method...
10106853 CUL4B as predictive biomarker for cancer treatment  
The current disclosure describes materials and methods for identifying subjects that would benefit from treatment with a DNA topoisomerase 1 inhibitor, based on the levels of cullin 4B gene, RNA...
10106778 Selective targeting of cancer stem cells  
Aspects of the invention relate to methods and related compositions for preferentially targeting cancer stem cells. In some embodiments, the methods utilize PKC-α/FRA1 pathway inhibitors to target...
10106532 Inhibitors of beta-hydroxylase for treatment of cancer  
The present invention relates to compounds which modulate (e.g., inhibit) the activity of beta-hydrolase (e.g., ASPH), including novel 2-aryl-5-amino-3(2H)-furanone and...
10106510 Substituted isoxazoles for treating cancer  
The present disclosure provides substituted cyclohexylamine compounds having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, R5,...
10106507 Potent dual BRD4-kinase inhibitors as cancer therapeutics  
Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects,...
10105436 Smallpox vaccine for cancer treatment  
Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an...
10105383 Therapy regimen and methods to sensitize cancer cells treated with epigenetic therapy to PARP inhibitors in lung cancer  
The presently disclosed subject matter provides methods to treat cancer cells using low doses of DNA demethylating agents and poly ADP ribose polymerase (PARP) inhibitors. Methods also are...
10105382 Therapy regimen and methods to sensitize cancer cells treated with epigenetic therapy to PARP inhibitors in ovarian cancer  
The presently disclosed subject matter provides methods to treat cancer cells using low doses of DNA demethylating agents and poly ADP ribose polymerase (PARP) inhibitors. Methods also are...
10105357 Indication of antibiotic drugs for preparation of cancer inhibition pharmaceutical composition  
A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of an antibiotic drug or a...
10105346 Isoflavonoid compounds and methods for the treatment of cancer  
Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in...
10105090 Method for representations of network-dependent features of the hemoglobin signal in living tissues for detection of breast cancer and other applications  
A non-invasive method of detecting anomalous tissue, such as cancerous or injured tissue, in a patient. At least two hemoglobin signal components of hemoglobin levels in at least one segment of...
10105058 Orbital angular momentum and fluorescence- based microendoscope spectroscopy for cancer diagnosis  
An apparatus for performing an endoscopic procedure for detecting cancerous tissue includes a detection probe for detecting the cancerous tissue. The detection probe includes a first fiber for...
10101334 Multiplex MRM assay for evaluation of cancer  
The current disclosure provides specific peptides, and derived ionization characteristics of the peptides from the estrogen receptor (ER), progesterone receptor (PR), and/or antigen Ki67 (Ki67)...
10101330 Protein and autoantibody biomarkers for the diagnosis and treatment of lung cancer  
Aspects of the present disclosure include methods of producing a circulating analyte profile of a subject. The methods include contacting a blood sample from a subject with a panel of probes for...
10100314 Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy  
In one embodiment, a single modality cancer immunotherapy regimen that includes a therapeutic composition is provided. Such a therapeutic composition may include a Salmonella strain comprising a...
10100119 Anti-human interleukin-1 receptor accessory protein antibody and its use for treating cancer  
The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or...
10100078 Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds  
The present invention regards nanoparticles comprising a sterol and a component derived from Quillaja saponaria Molina selected from quillaja acid and quillaja saponin, which nanoparticles do not...
10100034 Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts  
The present invention relates a new process to synthesize 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin -7-yloxy)methyl)cyclopropanamine (AL3818). A stable crystalline form of...
10100019 N2-(2-methoxyphenyl)pyrimidine derivative, method for preparing same, and pharmaceutical composition for cancer prevention or treatment containing same as active ingredient  
The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising...
10098952 Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer  
The present application relates to activable inorganic nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cancerous cells,...
10098933 Compositions of engineered human arginases and methods for treating cancer  
Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate...
10098917 Parovirus having a CpG-enriched genome useful for cancer therapy  
A parvovirus characterized by a CpG-enriched genome, wherein the genome contains at least 2 additional CpG inserts that are not present in the wild type genome is described as well as the use of...
10098900 Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases  
Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the...
10098880 Combination of nelfinavir, metformin and rosuvastatin for treating cancer caused by aberrations in PTEN/TP53  
The present disclosure relates to a method of treating cancer using a composition comprising Nelfinavir, Metformin, Rosuvastatin, optionally along with a pharmaceutically acceptable excipient. The...
10098860 Bezafibrate for the treatment of cancer  
Methods of treating renal cancer, including renal cell carcinoma, using bezafibrate are disclosed herein. Bezafibrate can be administered as a monotherapy or as part of a comprehensive treatment...
10098852 Indication of monobenzone pharmaceutical composition for treating cancer  
A method for treating a cancer includes administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising Monobenzone or a pharmaceutical...
10096110 System and method for automated stereology of cancer  
This invention relates to a system and method for applying an ensemble of segmentations to microscopy images of a tissue sample to determine if the tissue sample is representative of cancerous...
10095829 Computer implemented methods of treating lung cancer  
The present invention concerns a method for predicting the relative efficacy of a plurality of drugs for treating a tumor in an individual comprising the molecular characterization of the tumor,...
10094837 Cadherins as cancer biomarkers  
Methods of isolating, enriching, capturing, identifying, or detecting the presence of, cancerous cells in a sample, e.g., a blood sample from a subject, by detecting the presence of one or more...
10094834 Method of selecting individualized brain cancer therapy  
The present invention relates to a method of selecting individualized brain cancer therapy on the basis of the patient's PME-1 expression level in the diseased tissue.
10094832 Cervical cancer-related HPV E7 protein monoclonal antibody and use thereof  
The present invention provides an anti-HPV E7 protein monoclonal antibody and the use thereof. The antibody can detect the HPV16 E7 protein with high specificity and recognize the HPV18 E7...
10093977 Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them  
Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or...
10093934 SDF-1 binding nucleic acids and the use thereof in cancer treatment  
The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the...
10093930 Targeting WSB1 and pVHL to treat cancer  
Materials and methods for treating cancer (e.g., by reducing metastasis) are provided herein. For example, materials and methods for treating cancer by targeting WSB1 and/or pVHL are provided.